Evp4593

DescriptionQNZ (545380-34-5) was originally described as a potent inhibitor of NF-κB activation (IC50= 11 nM) and TNF-αproduction (IC50= 7 nM).1,2It indirectly inhibits the NF-κB pathway via inhibition of store-operated calcium entry (SOC) and displayed neuroprotective effects in transgenic fly and mouse models of Huntington’s disease.3,4Its target has been postulated to be heteromeric calcium channels containing TRPC1 as one of the subunits.4QNZ reduced synaptic neuronal SOC and rescued dendritic spine loss in YAC128 striatal medium spiny neurons.5QNZ has also been identified as a potent (IC50= 25 nM complex 1 fromY.lipolytica; IC50= 14 nM complex 1 fromBos Taurusheart mitochondria) and selective inhibitor of mitochondrial complex I.6QNZdecreased PSEN1ΔE9-mediated nSOCE upregulation and rescued mushroom spines in PSEN1ΔE9-expressing neurons, which are linked to familial Alzheimer’s disease.7

UsesQNZ is a novel inhibitor of NFkB which displays potent inhibitory effects on both NFKB transcriptional activation (IC50=11nM) and TNF-a production (IC50=7nM). It dose-dependently inhibited carragenin-induced edema formation in the rat paw model (1m

UsesQNZ is an inhibitor of NF-κB activation with IC50 of 11 nM.